Medical News Today published a short report headlined that three antidepressants may be best for long-term treatment of depression. The article metadata available in the supplied file lists Amy McLean as the author and November 13, 2026, as the publication date; the piece was fact-checked by Jill Seladi-Schulman, Ph.D. The excerpt provided here does not include the main text of the story, however, and therefore does not identify the three drugs, the evidence base, or any numerical outcomes.
This absence matters. Clinicians require trial characteristics, effect sizes, and safety data before altering maintenance prescriptions. The supplied content did not provide those elements. Readers should treat the headline as an indexical pointer to underlying research rather than as a standalone clinical recommendation.
The headline asserts superiority for three unspecified antidepressants in long-term management of depression. The supplied material did not report which agents were referenced, nor did it include primary study citations, trial registries, or guideline endorsements. No information was presented about study populations, duration of follow-up, or comparator treatments.
Equally absent were efficacy metrics—response rates, remission rates, relapse-prevention statistics—and any statistical measures that would allow appraisal of clinical significance. Safety outcomes and tolerability profiles across maintenance phases were not in the excerpt. Those omissions make it impossible to judge benefit–risk trade-offs from the provided text alone.
Which specific antidepressants were evaluated? The source did not say. What was the study design—randomized controlled trial, observational cohort, network meta-analysis? The material did not report this. How long was "long-term" in the study—months, years? Not reported. What patient groups were included—first-episode, recurrent major depressive disorder, older adults, comorbid medical illness? Not reported.
Other critical unknowns include dosing regimens, criteria for continuation versus discontinuation, tapering approaches, and whether psychosocial treatments were combined with pharmacotherapy. The supplied excerpt also omitted any safety signals, monitoring recommendations, or subgroup analyses. These are core components clinicians need to assess external validity and to judge whether findings apply to their patients.
Do not change maintenance antidepressant prescribing solely on the basis of this headline. Instead, obtain and read the primary study or guideline that the Medical News Today piece references. Look for the following when you access the original source: trial design, sample size, population characteristics, prespecified endpoints (for example, relapse-free survival or time to recurrence), head-to-head comparisons, and detailed adverse-event data.
If you cannot locate the primary report immediately, treat the headline as informational only. Discuss medication adjustments with patients in the context of individual response history, prior tolerability, comorbidities, and patient preference. Maintain routine monitoring for emergent adverse effects during long-term therapy, and follow established clinical guidelines for duration and discontinuation planning.
For researchers, the incomplete public report highlights the value of clear media reporting that includes citations and transparent methodological detail. When summarizing clinical trials for lay or clinician audiences, always reference the primary manuscript and key numerical results so readers can assess applicability.
The supplied file contained only webpage header material and the article headline with author attribution; the core article text was missing. Because of that, no factual claims beyond the headline can be reported here without violating source-integrity rules. Specific drug names, effect sizes, safety outcomes, and trial methods were not available in the excerpt, and so were not included in this rewrite.
Until the full article or, preferably, the underlying primary research is reviewed, clinicians and policy makers should withhold practice changes based solely on the headline. Key unanswered questions remain: Which agents? What magnitude of benefit? Which patients? What harms? Those are the precise questions to resolve when the primary sources are consulted.